Streetbeat News

Products Services

ELVN

Enliven Therapeutics Inc (NASDAQ:ELVN) released Phase 1 clinical trial data for ELVN-001, a kinase inhibitor targeting BCR-ABL gene fusion in CML patients. The trial showed a 44% major molecular response rate at 12 weeks, with no significant toxicities, supporting once-daily dosing. ELVN shares surged 23.60% to $24.50.

Portfolio Pulse from Vandana Singh

April 11, 2024 | 5:44 pm

GOOG

META

BofA Securities analyst Justin Post has reiterated a Buy rating on Meta Platforms, Inc. (NASDAQ:META) with a forecast of $550, citing the significant role of AI/ML integrations in boosting usage and ad spending in 2024. These integrations are expected to enhance content engagement, ad creative generation, campaign optimization, ad measurement, and back-end campaign cost savings for advertisers. Meta's focus on AI improvements and the upcoming release of LLAMA3 models are highlighted as key drivers. The analyst also notes Meta's competitive advantage over most online ad companies, including Alphabet Inc. (NASDAQ:GOOG), due to its compute infrastructure, LLM, and user data. However, there's speculation about investment shifts from the Metaverse to AI. LLAMA3, with 140 billion parameters, is anticipated to rival leading LLMs like GPT4.

Portfolio Pulse from Nabaparna Bhattacharya

April 11, 2024 | 5:43 pm

SOFI

Smart money investors have shown a bullish stance on SoFi Technologies (NASDAQ:SOFI), with 76% of detected trades being bullish. The options trading activity indicates a target price range of $5.0 to $15.0 for SOFI over the last 3 months. Recent trading volume and analyst ratings suggest a cautious but optimistic outlook for SOFI, with an average price target of $10.125 by four analysts. The company, known for its wide range of financial services, is approaching its earnings announcement, which could influence its stock price.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 5:31 pm

MGRM

NVDA

Monogram Orthopaedics Inc. (NASDAQ:MGRM) has been accepted into the NVIDIA Inception program, aimed at accelerating the development and commercialization of its mBôs robotic surgical system and related products. This collaboration will provide Monogram with access to NVIDIA's cutting-edge technology, expertise, and go-to-market support, potentially speeding up FDA clearance and product launch.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 5:22 pm

QTI

QT Imaging Holdings shares surged following the announcement of its partnership with the Center of New Medicine, focusing on personalized health care, cancer prevention, and early detection.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 5:20 pm

WAVE

Eco Wave Power's stock is trading higher following the announcement of a contract with an energy company to demonstrate wave energy harnessing at the port of Los Angeles.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 5:07 pm

SCHW

Charles Schwab Corporation (NYSE:SCHW) shares fell after announcing the launch of futures and forex trading on its thinkorswim platform, part of Schwab Trading Powered by Ameritrade. This expansion into forex trading marks Schwab's entry into this market, aiming to enhance its derivatives trading capabilities and offer a comprehensive trading experience.

Portfolio Pulse from Nabaparna Bhattacharya

April 11, 2024 | 5:05 pm

CHWY

Deep-pocketed investors are showing a bearish sentiment towards Chewy (NYSE:CHWY), with a significant move in options trading. Benzinga's tracking revealed 8 extraordinary options activities, with a bearish majority of 87%. The price target based on this activity ranges from $15.0 to $25.0. Chewy, a leading e-commerce pet care retailer, reported $11.2 billion in 2023 sales. The stock is currently up 4.48% at $18.18, with analysts giving mixed reviews and target prices ranging from $16 to $25.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 5:02 pm

EW

Analysts have recently updated their ratings and price targets for Edwards Lifesciences (NYSE:EW), showing a generally positive outlook. Over the last three months, 10 analysts offered diverse opinions, with recent updates indicating raised price targets and ratings ranging from 'Buy' to 'Neutral'. The average 12-month price target is now $96.00, up from $86.22, suggesting an 11.34% increase. Edwards Lifesciences, known for its medical devices for heart disease, shows strong financial performance with a solid revenue growth rate, impressive net margin, and ROE, alongside effective debt management.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 5:00 pm

MSFT

SPY

OpenAI CEO Sam Altman emphasized the importance of the U.S. developing a comprehensive AI policy, highlighting the rapid advancements in artificial intelligence and its implications for society and the economy. While the article mentions Microsoft (MSFT) and the SPDR S&P 500 ETF Trust (SPY) in relation to the broader market and technology sector's interest in AI, the focus remains on the call for regulatory frameworks.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 4:57 pm